Recruitment status changed
Before: Enrolling by invitation. After: Terminated.
Among the trials TrialRedline tracks, 76 changed their ClinicalTrials.gov record in October 2026: 6 status changes to terminated, withdrawn or suspended, 23 primary outcome text edits, 15 completion dates moved later, 7 completion dates moved earlier, 21 enrollment changes, 37 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
6 in October 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Enrolling by invitation. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Completed. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Completed. After: Terminated.
23 in October 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean percentage change in BMI Time frame: From Baseline to Week 14. After: Measure: Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI) Description: BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate. Time frame: Baseline, Week 14.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy: Overall Survival Description: Overall survival is defined as the time from randomization to date of death due to any cause. Time frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.. After: Measure: Overall Survival Description: Overall survival is defined as the time from randomization to date of death due to any cause. Time frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Phase 2: Objective Response Rate (ORR) Description: ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Time frame: up to 6 months Measure: Phase 3: Progression-Free Survival (PFS) Description: PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first). Time frame: From randomization to first occurrence of progressive disease (PD) or death (up to 4 years) Measure: Phase 3: Overall Survival (OS) Description: OS is the time from randomization to death due to any cause Time frame: From randomization until death from any cause (up to 4 years). After: Measure: Phase 2: Objective Response Rate by investigator (ORRinv) Description: defined as the proportion of patients with complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, as determined by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: From randomization to progressive disease (PD) or death (up to 1 year) Measure: Phase 3: Progression-Free Survival by Investigator (PFSinv) Description: defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST 1.1, or death from any cause (whichever occurs first). Time frame: From randomization to PD or death (up to 4 years) Measure: Phase 3: Overall Survival (OS) Description: defined as the time from randomization to death from any cause. Time frame: From randomization until death from any cause (up to 4 years).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of facial vitiligo that combines the extent of facial involvement and degree of depigmentation. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks. After: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of the extent and degree of depigmentation affecting the face with scores ranging from 0 to 3.5, where higher scores indicate greater facial vitiligo involvement. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate Description: Change from baseline in gastric emptying rate was determined by the AUC by Gastric Emptying Breath Test (GEBT) at Day 28 after administration of PCS12852 or placebo. Time frame: ~28 days Measure: Change in Gastric Emptying Rate From Baseline Using t50 Metric for Gastric Emptying Rate Description: Time for 50% gastric emptying (t50) metric assessed by the GEBT Time frame: ~28 days Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28 Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28. After: Measure: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate Description: Change from baseline in gastric emptying rate was determined by the AUC by Gastric Emptying Breath Test (GEBT) at Day 28 after administration of PCS12852 or placebo. Time frame: ~28 days Measure: Change in Gastric Emptying Rate From Baseline Description: Time for 50% gastric emptying (t50) metric assessed by the GEBT Time frame: ~28 days Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28 Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: GA lesion growth rate Description: Change in GA lesion area as assessed by fundus autofluorescence (FAF) Time frame: Baseline to Month 12. After: Measure: Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area Description: GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed). Time frame: Baseline to Month 12.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52 Time frame: 52 Weeks. After: Measure: Mean change from baseline in Best Corrected Visual Acuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52 Time frame: 52 Weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective Response Rate Description: Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: First dose through up to 3 months. After: Measure: Objective Response Rate Description: Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: Up to 40 months.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects achieving a response who receive rusfertide compared to placebo. Description: Response is defined as absence of phlebotomy eligibility. Time frame: Week 20 through Week 32. After: Measure: Part 1a: Percentage of Participants Who Achieved Response Description: Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%. Time frame: From Weeks 20 to 32.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline to Week 48 in Daily Cornstarch Intake Time frame: Baseline, Week 48. After: Measure: Main Study: Percent Change From Baseline to Week 48 in Daily Cornstarch Intake (Grams) Description: The least square (LS) mean and standard error (SE) are based on mixed-model for repeated measures (MMRM) analysis. Time frame: Baseline, Weeks 24, 30, 36, 42 and 48 Measure: Japan Cohort: Percent Change From Baseline to Week 48 in Daily Cornstarch Intake (Grams) Time frame: Baseline, Weeks 24, 30, 36, 42 and 48.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence (number of patients) of target wound related AEs throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported local (target wound related) AEs Time frame: Throughout the study (week 2- week 15) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-15 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-15 weeks. After: Measure: Incidence (number of patients) of systemic and local adverse events (AEs) throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported systemic and local AEs Time frame: Throughout the study (week 2- week 17) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-17 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-17 weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years. After: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of serious adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Serious Adverse Events (SAEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported LVEF \<50% Time frame: Baseline to End of study, up to 5 years.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 100 Weeks. After: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 248 Weeks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants With Adverse Events Time frame: Baseline up to end of study (up to approximately 8 years) Measure: Number of Participants With Laboratory Parameters Abnormalities Description: Laboratory parameters include hematological, serum biochemistry, adrenal laboratories, and urine data. Time frame: Baseline up to end of study (up to approximately 8 years) Measure: Number of Participants With Abnormal Physical Findings Description: Physical findings include weight, physical examination data, systolic and diastolic blood pressure, radial pulse rate, and body temperature. Time frame: Baseline up to end of study (up to approximately 8 years). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. Time frame: Baseline up to end of study (up to approximately 15 years).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 24 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 24 months. After: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 12 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 12 months.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits Time frame: Baseline through Month 15. After: Measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits Time frame: Baseline through Month 15 Measure: Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits Time frame: Baseline through Month 24.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index Description: Increase of myocardial tissue expression of LAMP2 protein and decrease in left ventricular mass index (LVMI). Time frame: 12 Months post-infusion. After: Measure: Evaluation of Efficacy: Improvement as assessed via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index (LVMI) Description: Myocardial tissue expression of LAMP2 protein improved from baseline to ≥ Grade 1 (by IHC), AND, ≥ 10% decrease in LVMI from baseline. Time frame: 12 months post-infusion.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective Response Rate Description: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC Time frame: 5 years. After: Measure: Objective Response Rate Description: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators Time frame: 12 months.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in urine protein-to-creatinine ratio (UPCR) Time frame: Baseline (Day 1) and up to Week 24. After: Measure: Change from Baseline in urine protein-to-creatinine ratio (UPCR) (Part A) Time frame: Baseline (Day 1) and up to Week 24 Measure: Proportion of participants with TEAEs, serious adverse events (SAEs), and treatment-emergent adverse events of special interest (AESIs). (Part A) Time frame: Time Frame: Up to Week 52.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related) Time frame: From Screening (ICF signature) to Week 100 Measure: Number of participants with abnormal MRI results Time frame: From Baseline to Week 100 Measure: Number of participants with clinically significant changes in physical and neurological examination results Time frame: From Baseline to Week 74 Measure: Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) Time frame: From Baseline to Week 100 Measure: Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056 Time frame: From Baseline to Week 100. After: Measure: Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related) Time frame: From Screening (ICF signature) to Week 100 in study part 1 and 2, and from Rescreening (ICF signature) to Week 78 in the extension phase Measure: Number of participants with abnormal MRI results Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Number of participants with clinically significant changes in physical and neurological examination results Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056 Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher Description: Summaries of AEs will be based on TEAEs. A TEAE is an AE that emerges or worsens in the period from the first dose of study drug to 30 days after the last dose of study drug (Lead-In Phase). Time frame: Up to 2 years Measure: Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) Description: PFS according to RECIST v1.1 will be evaluated in patients receiving SRF388 in combination with atezolizumab plus bevacizumab compared to placebo in combination with atezolizumab plus bevacizumab (Randomized Phase). Time frame: Up to 2 years. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: A TEAE was defined as an AE that emerged or worsened in the period from the first dose of study drug to 30 days after the last dose of study drug. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section. Time frame: Up to approximately 37 months.
15 in October 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 30 Dec 2027. After: 4 Nov 2028.
Before: 31 Oct 2026. After: 31 Jul 2027.
Before: 31 Dec 2026. After: 31 May 2027.
Before: May 2029. After: Dec 2029.
Before: Nov 2026. After: Sep 2027.
Before: Jan 2027. After: Apr 2027.
Before: Aug 2026. After: Oct 2026.
Before: Aug 2026. After: Sep 2027.
Before: Jun 2027. After: Mar 2028.
Before: Mar 2028. After: Mar 2029.
Before: Jun 2028. After: Jun 2030.
Before: Oct 2026. After: Jan 2028.
Before: 27 May 2027. After: May 2028.
Before: Apr 2028. After: Jun 2028.
Before: Jan 2028. After: Jun 2028.
7 in October 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 15 Jan 2027. After: 4 Jan 2027.
Before: 1 Jan 2028. After: 29 Dec 2027.
Before: Jun 2027. After: Nov 2026.
Before: 30 Apr 2028. After: Nov 2027.
Before: Nov 2028. After: Nov 2027.
Before: May 2027. After: Mar 2027.
Before: Dec 2032. After: Dec 2027.
21 in October 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 880 participants (planned). After: 940 participants (actual).
Before: 50 participants (planned). After: 1 participants (actual).
Before: 410 participants (planned). After: 450 participants (planned).
NCT05922878 · Alto Neuroscience
Before: 321 participants (planned). After: 325 participants (planned).
Before: 300 participants (planned). After: 302 participants (actual).
Before: 600 participants (planned). After: 250 participants (planned).
Before: 225 participants (planned). After: 247 participants (actual).
Before: 100 participants (planned). After: 17 participants (actual).
Before: 230 participants (planned). After: 285 participants (planned).
Before: 375 participants (planned). After: 398 participants (actual).
Before: 180 participants (planned). After: 191 participants (actual).
Before: 49 participants (actual). After: 52 participants (actual).
Before: 180 participants (planned). After: 185 participants (planned).
Before: 256 participants (planned). After: 786 participants (planned).
Before: 70 participants (planned). After: 43 participants (actual).
Before: 270 participants (planned). After: 265 participants (actual).
Before: 90 participants (planned). After: 20 participants (actual).
Before: 14 participants (planned). After: 18 participants (planned).
Before: 120 participants (planned). After: 121 participants (actual).
Before: 100 participants (planned). After: 24 participants (planned).
Before: 869 participants (planned). After: 710 participants (actual).
37 in October 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Enrolling by invitation.
Before: Active not recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Enrolling by invitation.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Enrolling by invitation. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Enrolling by invitation. After: Active not recruiting.
Showing 25 of 37. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: October 2026”. https://trialredline.com/reports/2026-10
Based on public ClinicalTrials.gov record history. How we collect and check the data